Advertisement

Reactions Weekly

, Volume 1747, Issue 1, pp 245–245 | Cite as

Regorafenib

Various toxicities: 7 case reports
Case report
  • 16 Downloads
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

In a study, 7 patients (3 women and 4 men) aged between 61-85 years, were described, who developed fatigue, hypertension, hand-foot skin reaction, lactate dehydrogenase elevation, anorexia, fever or renal dysfunction 1 during treatment with regorafenib for metastatic cancer [routes, duration of treatment to reactions onsets and outcomes not stated].

Case 1: A 61-year-old woman developed fatigue during treatment with regorafenib for metastatic lymph nodes and lung cancer. The woman had a history of hepatitis-B, rectum cancer and peripheral neuropathy. She had previously received four standard chemotherapies including folinic acid, fluorouracil and oxaliplatin [FOLFOX], folinic acid, fluorouracil and irinotecan [FOLFIRI] with bevacizumab and cetuximab for rectum cancer. She had a...

Reference

  1. Nakashima M, et al. Seven cases of metastatic colorectal cancer treated with dose-reduced and duration-reduced regorafenib treatment. [Japanese]. Gan to Kagaku Ryoho 45: 1673-1676, No. 11, Nov 2018 [Japanese; summarised from atranslation] - JapanGoogle Scholar

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations